Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Working Capital Changes (2018 - 2025)

UroGen Pharma's Other Working Capital Changes history spans 8 years, with the latest figure at -$3.9 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 18.52% year-over-year to -$3.9 million; the TTM value through Dec 2025 reached -$639000.0, up 38.2%, while the annual FY2025 figure was -$639000.0, 38.2% up from the prior year.
  • Other Working Capital Changes reached -$3.9 million in Q4 2025 per URGN's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.0 million in Q4 2021 to a low of -$5.8 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is $24650.0, with a median of -$257000.0 recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: crashed 2040.15% in 2023, then surged 1870.48% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $5.0 million in 2021, then plummeted by 105.35% to -$269000.0 in 2022, then plummeted by 2040.15% to -$5.8 million in 2023, then increased by 16.52% to -$4.8 million in 2024, then increased by 18.52% to -$3.9 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Other Working Capital Changes are -$3.9 million (Q4 2025), $4.6 million (Q3 2025), and -$5.5 million (Q2 2025).